FRA:LP6 (China)
Â
Class H
€
3.02
+0.020 (+0.67%)
Mar 27
What is a stock summary page? Click here for an overview.
Business Description
Livzon Pharmaceutical Group Inc
NAICS : 325412
ISIN : CNE100001QV5
Share Class Description:
FRA:LP6: Class HCompare
Compare
Traded in other countries / regions
000513.China01513.Hong KongLP6.GermanyLVZPF.USA IPO Date
2014-01-23Description
Livzon Pharmaceutical Group Inc is engaged in China's healthcare sector. As a pharmaceutical manufacturer, the company's portfolio comprises Western pharmaceutical preparations, bulk drugs, traditional Chinese medicines, as well as diagnostic reagents and equipment. Its drug address serious conditions such as gastrointestinal, cardiovascular, anti-infectious, antimicrobial, antineoplastic, hemopoietic system, and other conditions. It distributes its products within domestic markets and to overseas markets. It operates in a single reportable segment in PRC which is pharmaceutical manufacturing.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.74 | |||||
| Equity-to-Asset | 0.57 | |||||
| Debt-to-Equity | 0.29 | |||||
| Debt-to-EBITDA | 1.38 | |||||
| Interest Coverage | 31.94 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 3.83 | |||||
| Beneish M-Score | -2.71 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -0.2 | |||||
| 3-Year EBITDA Growth Rate | 8.3 | |||||
| 3-Year EPS without NRI Growth Rate | 7.3 | |||||
| 3-Year FCF Growth Rate | 60.3 | |||||
| 3-Year Book Growth Rate | 3.1 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 53.65 | |||||
| 9-Day RSI | 50.52 | |||||
| 14-Day RSI | 49.13 | |||||
| 3-1 Month Momentum % | -6.71 | |||||
| 6-1 Month Momentum % | -1.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.15 | |||||
| Quick Ratio | 1.89 | |||||
| Cash Ratio | 1.43 | |||||
| Days Inventory | 179.53 | |||||
| Days Sales Outstanding | 65.59 | |||||
| Days Payable | 151.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 5.76 | |||||
| Dividend Payout Ratio | 0.57 | |||||
| 3-Year Dividend Growth Rate | 2.6 | |||||
| Forward Dividend Yield % | 5.76 | |||||
| 5-Year Yield-on-Cost % | 8.44 | |||||
| 3-Year Average Share Buyback Ratio | 1 | |||||
| Shareholder Yield % | 4.47 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 65.45 | |||||
| Operating Margin % | 23.96 | |||||
| Net Margin % | 17.45 | |||||
| FCF Margin % | 20.38 | |||||
| ROE % | 14.6 | |||||
| ROA % | 8.23 | |||||
| ROIC % | 20.92 | |||||
| 3-Year ROIIC % | 56.29 | |||||
| ROC (Joel Greenblatt) % | 63.1 | |||||
| ROCE % | 17.56 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 16.09 | |||||
| Forward PE Ratio | 9.75 | |||||
| PE Ratio without NRI | 15.19 | |||||
| Shiller PE Ratio | 18.04 | |||||
| Price-to-Owner-Earnings | 25.36 | |||||
| PEG Ratio | 1.65 | |||||
| PS Ratio | 2.81 | |||||
| PB Ratio | 2.37 | |||||
| Price-to-Tangible-Book | 2.5 | |||||
| Price-to-Free-Cash-Flow | 13.8 | |||||
| Price-to-Operating-Cash-Flow | 11.15 | |||||
| EV-to-EBIT | 7.88 | |||||
| EV-to-EBITDA | 7.88 | |||||
| EV-to-Revenue | 1.93 | |||||
| EV-to-FCF | 9.47 | |||||
| Price-to-GF-Value | 0.97 | |||||
| Price-to-DCF (Earnings Based) | 0.64 | |||||
| Price-to-DCF (FCF Based) | 0.44 | |||||
| Price-to-Graham-Number | 1.37 | |||||
| Price-to-Net-Current-Asset-Value | 5.64 | |||||
| Price-to-Net-Cash | 102.97 | |||||
| Earnings Yield (Greenblatt) % | 12.69 | |||||
| FCF Yield % | 8.18 | |||||
| Forward Rate of Return (Yacktman) % | 11.43 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Livzon Pharmaceutical Group Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1,518.122 | ||
| EPS (TTM) (€) | 0.287 | ||
| Beta | 0.32 | ||
| 3-Year Sharpe Ratio | 0.02 | ||
| 3-Year Sortino Ratio | 0.03 | ||
| Volatility % | 23.97 | ||
| 14-Day RSI | 49.13 | ||
| 14-Day ATR (€) | 0.051254 | ||
| 20-Day SMA (€) | 3 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 2.58 - 3.82 | ||
| Shares Outstanding (Mil) | 911.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Livzon Pharmaceutical Group Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Livzon Pharmaceutical Group Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Livzon Pharmaceutical Group Inc Frequently Asked Questions
What is Livzon Pharmaceutical Group Inc(FRA:LP6)'s stock price today?
The current price of FRA:LP6 is €3.02. The 52 week high of FRA:LP6 is €3.82 and 52 week low is €2.58.
When is next earnings date of Livzon Pharmaceutical Group Inc(FRA:LP6)?
The next earnings date of Livzon Pharmaceutical Group Inc(FRA:LP6) is .
Does Livzon Pharmaceutical Group Inc(FRA:LP6) pay dividends? If so, how much?
The Dividend Yield %  of Livzon Pharmaceutical Group Inc(FRA:LP6) is 5.76% (As of Today), Highest Dividend Payout Ratio of Livzon Pharmaceutical Group Inc(FRA:LP6) was 1.16. The lowest was 0.06. And the median was 0.68. The  Forward Dividend Yield % of Livzon Pharmaceutical Group Inc(FRA:LP6) is 5.76%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers